AS601245

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties[1][2].

Product Specifications

CAS Number

[345987-15-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JNK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/AS601245.html

Concentration

10mM

Purity

98.19

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

N#CC(C1=CC=NC(NCCC2=CC=CN=C2)=N1)C3=NC4=CC=CC=C4S3

Molecular Formula

C20H16N6S

Molecular Weight

372.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Carboni S, et al. AS601245 (1,3-benzothiazol-2-yl (2-[[2- (3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile) : a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004;310 (1) :25-32.